ACTION, AWARENESS, HOPE
Lung Cancer Awareness Month – Thank You!
Thank you to everyone who helped make Lung Cancer Awareness Month such a powerful and inspiring moment for the lung cancer community. Throughout November, we elevated the importance of early detection, advanced lifesaving research, and honored the strength and resilience of those impacted by lung cancer.
This year’s centerpiece was the striking White Flags over Washington installation on the National Mall with 60,000 flags each symbolizing two lives lost to lung cancer each year and underscoring the urgency to act.
Across the country, thousands joined our Breathe Deep TOGETHER events in Boston, Washington, D.C., New York City, and virtually through Breathe Deep Anywhere, building community and raising critical awareness.
We also highlighted the promise of research and innovation through expert conversations, educational materials, and stories from survivors and caregivers. Screening events took place, city and state proclamations were made, stories were covered by the media, and so much more to highlight lung cancer this month. These collective efforts helped broaden understanding, spark action, and reinforce that anyone with lungs can get lung cancer, and with awareness, research, and screening, we can save more lives.
Thank you for standing with us. Together, we’re driving progress and bringing hope to all those affected by lung cancer.
Your Year-End Gift Saves Lives
Lung cancer action doesn’t stop in November. Help accelerate early detection research, support patients, and drive the breakthroughs that bring hope to every person diagnosed with lung cancer.
Give by December 31 and make a lifesaving impact.
Through our partnership with FreeWill, everyone connected to LUNGevity is welcome to create a no-cost, legally-binding will in as little as 20 minutes. If you don't yet have an official will or estate plan in place, this is an easy way to make sure the people you care about most are taken care of in the future.
SCIENCE & RESEARCH CORNER
Every day, patients and researchers around the world work together to improve the way we diagnose and treat lung cancer.
Those efforts have compounded over the past few decades to create significant breakthroughs for patients with lung cancer.
BiTE® Therapy: Learn More About the SCLC Treatment
On November 19, 2025, the FDA granted full approval to tarlatamab, an exciting first-in-class drug, to treat patients with ES-SCLC. A bi-specific T-cell engager, BiTE® is a novel type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the body’s immune response, to attack tumor cells. Learn how this revolutionary BiTE® therapy works in our educational video and be sure to check out the discussion guide for FAQs and questions to ask your care team.
Powering Progress: Your Generosity Fuels Critical Lung Cancer Research
This November, we celebrated Lung Cancer Awareness Month with the announcement of our 2025 cohort of research awardees. This critical support is made possible by LUNGevity’s partners, donors, and supporters, like you, who are committed to building strong pipelines of innovative lung cancer research.
By funding the next generation of scientists and accelerating lifesaving discoveries for patients, this support drives real progress. Below, you can learn more about the research funded by LUNGevity this year and you can learn about a new FDA approval for treating lung cancer—evidence of what happens when we invest in strong science.
Generosity at Work: $1.2 Million for New Lung Cancer Research
LUNGevity is proud to support the next generation of lung cancer research with $1.2 million in research awards. These awards strengthen scientific efforts across the lung cancer continuum—from early detection to advanced treatments—ensuring today's breakthroughs lead to tomorrow's cures.
As federal funding remains uncertain, research support is even more important than ever to keep brilliant minds focused on solving lung cancer's biggest challenges.
This year's awardees are early-career investigators bringing fresh perspectives and transformative ideas to the field. Learn more about the exciting research selected by lung cancer experts and fueled by LUNGevity supporters.
FDA Approval for HER2-Positive NSCLC
On November 19, 2025, the US Food and Drug Administration announced the accelerated approval of sevabertinib to treat patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with specific mutations in the HER2 gene. This approval is for patients who have been approval is for patients who have received previous systemic treatment that did not target HER2. Learn more.
Don't Miss Out!
Our research newsletter keeps you up to date on all the latest scientific developments in lung cancer. Subscribe now and watch for the next issue coming soon.
Take Action Before the Year Ends!
On November 20, Representatives Castor (D-FL), Fitzpatrick (R-PA), and Wasserman Schultz (D-FL) reintroduced the Increasing Access to Lung Cancer Screening Act. This legislation is a top priority for LUNGevity and our partners. It would ensure that everyone currently recommended for lung cancer screening can get screened without cost-sharing and prior authorization.
It would also establish a nationwide education campaign on lung cancer screening and authorize a study to better understand populations at increased risk for lung cancer but not included in the current guidelines. Additionally, it would expand access to tobacco cessation services in Medicaid. You can read our statement on the bill's reintroduction here and write your representative to ask for their support using this campaign.
Join the LUNGevity Action Network! To receive our latest newsletters and advocacy updates, please sign up for our email list. We also invite you to share your story and to find additional campaigns for action on topics like lung cancer research funding and telehealth access on our Take Action page.
Team LUNGevity: Year in Review
- 212 athletes laced up for Team LUNGevity in 2025.
- They came from 27 U.S. states, plus D.C., Puerto Rico, and 6 countries.
- Among them: 6 survivors and 51 returning teammates.
- Together, they powered through 4,500 miles across 24 events.
- And turned every step into impact—raising $600K and counting!
Be a part of the team in 2026 and help us race to stop lung cancer, one mile at a time.
🍇 Kaiser Permanente Napa Valley Marathon & Half Marathon
🍎 United Airlines NYC Half
🌊 Big Sur International Marathon
🌍 Sanlam Cape Town Marathon
🌲 Grandma’s Marathon
🐨 TCS Sydney Marathon presented by ASICS
Watch Now: Climate Change, Air Pollution, and Lung Cancer
There's still time to hear from all the experts who presented at LUNGevity's International Lung Cancer Survivorship Conference (ILCSC) in September. All recordings remain available until December 31, including the detailed talk: The Role of Climate Change and Air Pollution in Lung Cancer by Joan Schiller, MD, Oncology Advocates United for Climate and Health.
Dr. Schiller's presentation touches on:
- How pollution affects people with cancer
- Consequences of climate change
- Indoor and outdoor air pollution
- How you can advocate for cleaner air
If you previously registered for ILCSC, simply log in to watch all the recordings. Otherwise, create an account through the button below.
Step Into Screening
On November 15, LUNGevity partnered with Memorial Sloan Kettering Cancer Center (MSK) and the MSK Ralph Lauren Center to plan and host the first multi-cancer screening outreach event in Harlem. Community members were able to receive breast, cervical, colorectal, and prostate cancer screenings at the MSK Ralph Lauren Center, and MSK provided a shuttle to the Koch Center for lung cancer screening. The event demonstrated the power of partnership in expanding access to cancer prevention and care.
LUNGevity will host the second annual Spring into Screening event in Washington, D.C. in March 2026.
Texas Lung Cancer Lunch & Learn
The LUNGevity Texas Lung Cancer Lunch & Learn brought together leading experts from MD Anderson Cancer Center, UT Southwestern Medical Center, and UT Health San Antonio for a hybrid educational program focused on the latest advances in lung cancer research, treatment, and quality of life. Attendees joined both online and at an in-person watch party hosted by Cancer Support Community North Texas, gaining practical insights, resources, and support. We’re grateful to our partners and speakers for making this event a valuable experience for patients and caregivers across the region.
In Case You Missed It
LUNGevity is transforming what it means to be diagnosed and live with lung cancer.
Support our mission by making a tax-deductible donation today.
